https://scholars.lib.ntu.edu.tw/handle/123456789/495087
標題: | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | 作者: | Salto-Tellez M. Tsao M.-S. JIN-YUAN SHIH Thongprasert S. Lu S. Chang G.-C. Au J.S.-K. Chou T.-Y. Lee J.-S. Shi Y.-K. Radzi A. Kang J.-H. Kim S.-W. Tan S.-Y. CHIH-HSIN YANG |
公開日期: | 2011 | 出版社: | Lippincott Williams and Wilkins | 卷: | 6 | 期: | 10 | 起(迄)頁: | 1663-1669 | 來源出版物: | Journal of Thoracic Oncology | 摘要: | Background: Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols. Methods: A consensus meeting was held involving expert oncologists, pulmonologists, and pathologists to discuss the current status and variations in EGFR mutation testing of NSCLC across Asia and to recommend a standard clinical and laboratory testing approach for future use. Results: Currently, EGFR mutation tests are only routinely performed in some East Asian countries and medical centers. The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations. To increase the sensitivity and specificity of the EGFR mutation tests, tissue acquisition and pretest sample evaluation are important steps in addition to standardization of the EGFR mutation test methodology. Conclusion: A standardized EGFR mutation testing protocol is an essential step toward realization of personalized medicine in East Asian NSCLC treatment. ? 2011 by the International Association for the Study of Lung Cancer. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053023140&doi=10.1097%2fJTO.0b013e318227816a&partnerID=40&md5=2f8c068f183baf9ff597b80274645bd9 https://scholars.lib.ntu.edu.tw/handle/123456789/495087 |
ISSN: | 1556-0864 | DOI: | 10.1097/JTO.0b013e318227816a | SDG/關鍵字: | epidermal growth factor receptor; gefitinib; protein tyrosine kinase inhibitor; article; Asia; Canada; cancer staging; China; conceptual framework; consultation; cytology; denaturing high performance liquid chromatography; DNA extraction; evaluation; false negative result; fluorescence in situ hybridization; gene dosage; gene mutation; gene sequence; genetic analysis; genetic screening; health care cost; high resolution melting analysis; histology; Hong Kong; human; immunohistochemistry; lung non small cell cancer; Malaysia; microdissection; national health insurance; pleura effusion; polymerase chain reaction; practice guideline; priority journal; progression free survival; protein expression; quality control; sensitivity and specificity; sex difference; Singapore; smoking; South Korea; standardization; Taiwan; Thailand; tumor biopsy; tumor cell; turnaround time |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。